Carly Loudermilk, Joshua Eudy, Stephanie Albrecht, Cara N Slaton, Stefanie Stramel, Patrick Tu, Benjamin Albrecht, Sarah B Green, Jeannette L Bouchard, Alison I Orvin, Christian F Caveness, Andrea Sikora Newsome, Christopher M Bland, Daniel T Anderson
{"title":"对粪肠球菌血流感染的序贯口服抗生素治疗与静脉注射抗生素治疗进行评估。","authors":"Carly Loudermilk, Joshua Eudy, Stephanie Albrecht, Cara N Slaton, Stefanie Stramel, Patrick Tu, Benjamin Albrecht, Sarah B Green, Jeannette L Bouchard, Alison I Orvin, Christian F Caveness, Andrea Sikora Newsome, Christopher M Bland, Daniel T Anderson","doi":"10.1177/10600280241260146","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by <i>Enterococcus faecalis</i>.</p><p><strong>Objective: </strong>To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with <i>E faecalis</i> BSI.</p><p><strong>Methods: </strong>Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for <i>E faecalis</i> from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate.</p><p><strong>Results: </strong>Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; <i>P</i> < 0.001).</p><p><strong>Conclusion and relevance: </strong>Sequential oral therapy for <i>E faecalis</i> BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"127-133"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of <i>Enterococcus faecalis</i> Bloodstream Infections.\",\"authors\":\"Carly Loudermilk, Joshua Eudy, Stephanie Albrecht, Cara N Slaton, Stefanie Stramel, Patrick Tu, Benjamin Albrecht, Sarah B Green, Jeannette L Bouchard, Alison I Orvin, Christian F Caveness, Andrea Sikora Newsome, Christopher M Bland, Daniel T Anderson\",\"doi\":\"10.1177/10600280241260146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by <i>Enterococcus faecalis</i>.</p><p><strong>Objective: </strong>To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with <i>E faecalis</i> BSI.</p><p><strong>Methods: </strong>Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for <i>E faecalis</i> from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate.</p><p><strong>Results: </strong>Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; <i>P</i> < 0.001).</p><p><strong>Conclusion and relevance: </strong>Sequential oral therapy for <i>E faecalis</i> BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.</p>\",\"PeriodicalId\":7933,\"journal\":{\"name\":\"Annals of Pharmacotherapy\",\"volume\":\" \",\"pages\":\"127-133\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10600280241260146\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280241260146","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Evaluation of Sequential Oral Versus Intravenous Antibiotic Treatment of Enterococcus faecalis Bloodstream Infections.
Background: Intravenous (IV) antibiotics have historically been considered standard of care for treatment of bloodstream infections (BSIs). Recent literature has shown sequential oral (PO) therapy to be noninferior to IV antibiotics for certain pathogens and disease states. However, a gap exists in the literature for BSI caused by Enterococcus faecalis.
Objective: To compare outcomes of definitive sequential PO therapy to definitive IV therapy in patients with E faecalis BSI.
Methods: Multicenter, retrospective, matched cohort study of adult patients with at least one blood culture positive for E faecalis from January 2017 to November 2022. Patients with polymicrobial BSI, concomitant infections requiring prolonged IV antibiotic therapy, those who did not receive antibiotic therapy, and those who died within 72 hours of index culture were excluded. Subjects were matched based on source of infection in a 2:1 (IV:PO) ratio. The primary outcome was a composite of all-cause mortality and treatment failure. Secondary outcomes included hospital length of stay (LOS), antibiotic duration, and 30-day readmission rate.
Results: Of the 186 patients who met criteria for inclusion, there was no statistically significant difference in the primary composite outcome for PO compared to IV therapy (14.5% vs 21.8%; OR 0.53 [0.23-1.25]) or 30-day readmission (17.5% vs 29%; OR 0.53 [0.25-1.13]). Hospital LOS was significantly longer in patients receiving IV-only therapy (6 days vs 14 days; P < 0.001).
Conclusion and relevance: Sequential oral therapy for E faecalis BSI had similar outcomes compared to IV-only treatment and may be considered in eligible patients.
期刊介绍:
Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days